Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToPiND: Tofogliflozin vs pioglitazone on hepatic steatosis in NAFLD with type 2 diabetes
jRCTs031180159Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin and pioglitazone in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in liver fat content (MRI-PDFF). Started Feb 2018; status: completed.
02
Drugs
tofogliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs031180159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180159.